225 related articles for article (PubMed ID: 33323380)
1. A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models.
Fontaine SD; Ashley GW; Houghton PJ; Kurmasheva RT; Diolaiti M; Ashworth A; Peer CJ; Nguyen R; Figg WD; Beckford-Vera DR; Santi DV
Cancer Res; 2021 Feb; 81(4):1076-1086. PubMed ID: 33323380
[TBL] [Abstract][Full Text] [Related]
2. Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
Zhang D; Singh B; Moerland J; Mitchell O; Lockwood L; Carapellucci S; Sridhar S; Liby KT
Sci Rep; 2021 Jan; 11(1):1234. PubMed ID: 33441637
[TBL] [Abstract][Full Text] [Related]
3. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
6. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
[TBL] [Abstract][Full Text] [Related]
7. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
[TBL] [Abstract][Full Text] [Related]
9. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
McCann KE
Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
[TBL] [Abstract][Full Text] [Related]
10. Sustained delivery of PARP inhibitor Talazoparib for the treatment of
Yang S; Green A; Brown N; Robinson A; Senat M; Testino B; Dinulescu DM; Sridhar S
Front Oncol; 2023; 13():1175617. PubMed ID: 37228496
[TBL] [Abstract][Full Text] [Related]
11. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
12. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
14. A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.
Fontaine SD; Carreras CW; Reid RR; Ashley GW; Santi DV
Cancer Res Commun; 2023 May; 3(5):908-916. PubMed ID: 37377899
[TBL] [Abstract][Full Text] [Related]
15. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
16. Sustained Release Talazoparib Implants for Localized Treatment of
Belz JE; Kumar R; Baldwin P; Ojo NC; Leal AS; Royce DB; Zhang D; van de Ven AL; Liby KT; Sridhar S
Theranostics; 2017; 7(17):4340-4349. PubMed ID: 29158830
[TBL] [Abstract][Full Text] [Related]
17. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
19. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.
Pai Bellare G; Sankar Patro B
Biochem Pharmacol; 2022 May; 199():115024. PubMed ID: 35367197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]